ChartRow logo
Data provided bySource: Twelve Data
AZN
$184.45+0.04%
as of close, Nov 13, 2026
☾ AH $184.45 +0.04%
PeersMRNALLYUNHMDTJNJTMO
Share this page

AZN — AstraZeneca PLC price, chart and key statistics

Technical analysis2
Overlay lines0
Addendum charts0
Data provided bySource: Twelve Data
What would $1,000 invested in AZN be worth today? →
AZN returns: By year · By month · By week · Trailing

Price data

Price
$184.45
YTD price return
+0.32%
YTD total return
+1.37%
52W low
$153.41
52W high
$212.71
From 52W high
-13.29%
From 52W low
+20.23%
52W range
52%$153–$213
Beta
0.26

Volume

Rel volume
0.62×
30D volume
3M
30D $ vol
519.6M

Insider trading

Insider net 1W
none
Insider net 1M
none
Insider net 3M
none
Insider net 1Y
−$2.2M

Form 4 transactions by trade date, as filed; latest on file 2026-08-08.

Fundamentals

EPS (ttm)
$6.54
FCF (ttm)
11.8B
Net margin
17.42%
ROE
21.03%
ROA
8.97%
Debt / equity
0.51×
Current ratio
0.94

Growth (CAGR, ttm) · 10Y

Sales
+8.64%+9.82%+17.16%+9.04%
Net income
+45.37%+45.91%+26.62%+13.73%
FCF
+18.41%+10.51%+25.12%+19.41%

Per-share growth (CAGR, ttm) · 10Y

EPS
+45.37%+45.79%+21.80%+11.36%
Dividend/share
+5.39%+2.58%+2.25%+1.13%
Price
+4.08%+13.12%+9.42%+12.66%
Total return
+5.17%+15.14%+11.56%+15.78%

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)
28.2×
Fwd P/E
16.3×
Dividend yield (ttm)Div yield (ttm)
1.73%

Vs own 10Y history

P/E
16th

Bar = where today’s multiple sits in AZN’s own 10-year range:near a decade-low (cheap)→mid-range→near a decade-high (rich).

Performance · price returntotal return · as of 2026-11-13#

Data provided bySource: Twelve Data
1D
+0.04%
5D
-1.06%
1M
+18.37%
3M
+17.30%
YTD
+0.32%
1Y
+4.08%
5Y
+56.85%
1D
+0.04%
5D
-1.06%
1M
+18.37%
3M
+17.30%
YTD
+1.37%
1Y
+5.16%
5Y
+72.87%

Fundamentals#

Revenue

5Y CAGR +17.2%10Y CAGR +9.0%
$58.7B FY25
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25

No quarters filed for this figure.

Operating income

5Y CAGR +21.6%5Y CAGR +21.6%
$13.7B FY25
FY17FY18FY19FY20FY21FY22FY23FY24FY25

No quarters filed for this figure.

EPS (diluted)

5Y CAGR +21.8%10Y CAGR +11.4%
$6.54 FY25
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25

No quarters filed for this figure.

Free cash flow

5Y CAGR +25.1%10Y CAGR +19.4%
$11.8B FY25
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25

FY25: operating cash flow $14.6B, capex −$2.8B

No quarters filed for this figure.

Shares (diluted)

5Y +19.0%10Y +23.5%
1.6B FY25
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25

No quarters filed for this figure.

Dividend per share

5Y CAGR +2.3%10Y CAGR +1.1%
$3.13 FY25
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25

No quarters filed for this figure.

Full AZN financials →

AstraZeneca PLC American Depositary Shares represent ownership in AstraZeneca PLC, a global biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. AstraZeneca’s current business spans Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. The company develops and markets treatments used across hospitals, clinics, and specialty care settings, serving patients and healthcare providers in major therapeutic areas with high unmet medical need. Its portfolio is built around branded medicines and regulated drug launches, with ongoing commercial activity across the United States, Europe, and other international markets. AstraZeneca PLC American Depositary Shares provide U.S. investors a way to hold an instrument linked to the company’s underlying shares while participating in the performance of one of the world’s largest research-driven drugmakers.

Cambridge, United Kingdom·96,100 employees·Drug Manufacturers - General·astrazeneca.com·As of Oct 28, 2026

Recent filings#

All filings and insider trades →

ETFs holding AZN#

10 of the 193 ETFs ChartRow carries live hold AZN. The 8 largest positions, by the weight each fund filed in its latest SEC N-PORT report (Jun 26 to Aug 26).

FundNameFiled weight
EWUiShares MSCI United Kingdom ETF7.6%
VGKVanguard FTSE Europe ETF1.6%
EFAiShares MSCI EAFE ETF1.2%
VEAVanguard FTSE Developed Markets ETF0.9%
VEUVanguard FTSE All-World ex-US ETF0.6%
VXUSVanguard Total International Stock ETF0.6%
URTHiShares MSCI World ETF0.3%
ACWIiShares MSCI ACWI ETF0.3%
TickerName1M1D
LLYEli Lilly and Company+23.75%+1.14%
JNJJohnson & Johnson+14.94%+0.79%
ABBVAbbVie Inc.+7.53%+0.20%
UNHUnitedHealth Group Incorporated Common Stock (DE)+7.86%+0.58%
MRKMerck & Co. Inc.+4.07%+0.55%
NVSNovartis AG+12.70%+0.16%
TMOThermo Fisher Scientific Inc.+5.61%+0.11%
AMGNAmgen Inc.+12.80%-0.30%